Back to News
Market Impact: 0.2
UBS Initiates Coverage of Praxis Precision Medicines with Buy
Source: Nasdaq
Analyst Insights
On October 15, 2026, UBS initiated coverage of Praxis Precision Medicines with a Buy recommendation, while HC Wainwright & Co. reiterated its Buy rating. The stock had closed at $239.02 before the rating actions; the article provides no subsequent share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PRAX0.65
UBS0.00
More News
- These tech stocks are a buy ahead of their earnings reports, Bank of America says
- Citi says interest rates may matter more for economy than stock valuations
- AI Selloff Tests Investor Confidence
- Chip Stocks Just Fell 8 Days in a Row, Their Longest Losing Streak Since 2008
- Neocloud Stock Collapse: Buying Opportunity or Run for the Hills?
- PNC Financial: Fed Pivot And NII Growth (Rating Upgrade)